Bifogade filer
20251201_PM_Isofol_Upcoming events
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
GOTHENBURG, Sweden, December 1, 2025 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces that the company will participate in several investor meetings during December and January to present the company and its drug candidate arfolitixorin.
The information in the press release is intended for investors.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, conducted at the German University Hospital Charité. The drug candidate has the potential to fill a known treatment gap in cancer care.
Isofol’s CEO Petter Segelman Lindqvist will present Isofol and the drug candidate arfolitixorin during the following events:
December 3, 2025 – Redeye Life Science Day, Stockholm, Sweden
December 4, 2025 – ABG Sundal Collier Investor Days, Stockholm, Sweden
January 12–15, 2026 – J.P. Morgan Healthcare Conference 2026, San Francisco, US
January 21, 2026 – Redeye Fight Cancer Day 2026, Stockholm, Sweden
Prior to these events, in November, Isofol participated in the Redeye Investor Forum and arranged an investor meeting. These and previous events can be viewed retrospectively on Isofol's website: www.isofolmedical.com
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on December 1, 2025.
About Isofol
Isofol Medical AB works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.